DiaMedica Therapeutics closed at $10.77 on Nov 4, up 7.70% — matching its 52-week closing high. Volume of 409.4K shares was 1.87× its 20-day average (above normal).
Split-adjusted performance: +32.5% over one month, +65.2% over six months, +58.4% over one year.
Short interest was 5.2M shares at the Oct 15 settlement, down 6.1% from the prior report (21.5% of float, 21.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DMACDiaMedica Therapeutics | $10.77 | +7.70% | +65.2% | — | — | — | $580.8M | |
| BCAXBicara Therapeutics | $8.89 | −0.78% | −62.6% | — | — | — | $588.3M | Compare |
| ACRSAclaris Therapeutics | $3.68 | −1.60% | −23.0% | −8.3% | −1320.1% | — | $570.3M | Compare |
| NVCTNuvectis Pharma | $18.47 | −4.50% | +84.7% | — | — | — | $602.9M | Compare |
| NGNENeurogene | $27.58 | +3.41% | −14.7% | — | — | — | $551.9M | Compare |
| PBYIPUMA BIOTECHNOLOGY | $10.69 | +4.60% | +43.5% | +7.8% | 14.5% | 20.7 | $551.8M | Compare |
| IRWDIronwood Pharmaceuticals, Inc. - | $3.77 | +7.71% | −21.9% | +32.6% | 45.4% | 4.8 | $623.0M | Compare |
| CLYMClimb Bio | $9.33 | −4.31% | −23.6% | — | — | — | $535.9M | Compare |
| OVIDOvid Therapeutics | $2.74 | +14.17% | −1.4% | −88.3% | −2047.6% | — | $535.1M | Compare |
No recent articles focused on DiaMedica Therapeutics. 1 articles mention it in passing.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
